<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951128</url>
  </required_header>
  <id_info>
    <org_study_id>Tranexamic Acid</org_study_id>
    <nct_id>NCT04951128</nct_id>
  </id_info>
  <brief_title>The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery</brief_title>
  <official_title>The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consultants in Ophthalmic and Facial Plastics Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consultants in Ophthalmic and Facial Plastics Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid (TXA) is a synthetic inhibitor of plasminogen lysine receptor that has used&#xD;
      to reduce intra-operative bleeding in a number of clinical scenarios. Anecdotally, TXA has&#xD;
      used by plastic surgeons to reduce post-operative bruising. To date, there is limited data to&#xD;
      valid the benefits and to evaluate the side effects of TXA. The objective of this study is to&#xD;
      evaluate the effect of local TXA on edema and ecchymosis in eyelid surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tranexamic acid (TXA) is a synthetic reversible competitive inhibitor to plasminogen lysine&#xD;
      receptor, which prevents plasmin formation and stabilizes the fibrin matrix, thus reduce&#xD;
      bleeding. Recent studies have demonstrated the antifibrinolytic benefits of TXA in a number&#xD;
      of clinical scenarios, including heavy menstrual bleeding, traumatic hemorrhage, elective&#xD;
      cesarean section, total knee arthroplasty, coronary artery surgery, spinal deformity surgery,&#xD;
      orthognathic surgery, transurethral prostate resection, aneurysmal subarachnoid hemorrhage,&#xD;
      epistaxis, and hemoptysis.&#xD;
&#xD;
      Anecdotally, TXA has been used by plastic surgeons to reduce postoperative bruising. However,&#xD;
      there is a paucity of clinical data on TXA use in plastic surgery, and the results are&#xD;
      inconsistent. In a prospective randomized controlled trial evaluating local TXA in upper&#xD;
      blepharoplasty, Sagiv et al reported no intraoperative blood loss, surgeon's assessment of&#xD;
      hemostasis, and periocular ecchymosis size on postoperative day 1. Butz and Geldner reviewed&#xD;
      their experience placing TXA-soaked pledgets in 57 patients who underwent face lift18. They&#xD;
      identified only 1 patient who had post-operative hematoma and they reported no systemic&#xD;
      complications from TXA use. In a randomized control trial evaluating topical TXA in reduction&#xD;
      mammoplasty, Ausen et al reported 39% reduction of postoperative fluid drainage on the&#xD;
      treatment side. In a study evaluating oral TXA and cortisone effect in rhinoplasty,&#xD;
      Sakalliogu et al reported significant reduction of intraoperative bleeding and postoperative&#xD;
      ecchymosis/edema in patients who underwent rhinoplasty. Further study is warranted to&#xD;
      evaluate the use to TXA in plastic surgery. The objective of this study is to evaluate the&#xD;
      effect of local TXA on edema and ecchymosis in eyelid surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Participants in this study will undergo bilateral upper/lower eyelid surgery. The treatment side with tranexamic acid will be randomized for each patient using a random coin flip generator (head for the right side and tail for left side). The surgeons, participants, and photo reviewers will be blinded to the treatment side.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative edema/ecchymosis</measure>
    <time_frame>1st post op visit: post-op day 1 to 3</time_frame>
    <description>Post-operative edema/ecchymosis will be graded by Winkler-Black Bruising Scale (0= no bruising, 1= mild bruising, 2=moderate bruising, 3=severe bruising)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative edema/ecchymosis</measure>
    <time_frame>2nd post op visit: post-op day 7 to 10</time_frame>
    <description>Post-operative edema/ecchymosis will be graded by Winkler-Black Bruising Scale (0= no bruising, 1= mild bruising, 2=moderate bruising, 3=severe bruising)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>1st post op visit: post-op day 1 to 3</time_frame>
    <description>Potential complications: allergic reaction, persistent bleeding, thromboembolic event, wound dehiscence, wound infection, or tissue necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>2nd post op visit: post-op day 7 to 10</time_frame>
    <description>Potential complications: allergic reaction, persistent bleeding, thromboembolic event, wound dehiscence, wound infection, or tissue necrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Edema</condition>
  <condition>Ecchymosis; Eyelid</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eyelid(s) that received tranexamic acid in the local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyelid(s) that receive local anesthetic without tranexamic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Tranexamic acid (100 mg/mL concentration; 0.5 mL) will be added to local anesthetic mixture of 2% lidocaine with epinephrine (2.25 mL) and 0.5% bupivacaine with epinephrine (2.25mL).</description>
    <arm_group_label>Tranexamic acid arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Local anesthetic control</intervention_name>
    <description>Local anesthetic mixture without tranexamic acid consisting of 2% lidocaine with epinephrine (2.5 mL) and 0.5% bupivacaine with epinephrine (2.5 mL).</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 18 years old&#xD;
&#xD;
          -  Undergo bilateral upper/lower eyelid blepharoplasty, bilateral upper eyelid ptosis&#xD;
             repair, or a combination of the above procedures&#xD;
&#xD;
          -  Additional concurrent forehead/brow or upper/lower eyelids surgeries may be included&#xD;
             if bilateral&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior eyelid surgery&#xD;
&#xD;
          -  Anticoagulant or antiplatelet use, including aspirin, within 7 days prior to surgery&#xD;
&#xD;
          -  Patient who is currently pregnant or breast feeding&#xD;
&#xD;
          -  Patient with color vision deficiency&#xD;
&#xD;
          -  TXA allergy&#xD;
&#xD;
          -  History of bleeding disorder&#xD;
&#xD;
          -  History of clotting disorder&#xD;
&#xD;
          -  History of seizure&#xD;
&#xD;
          -  Have active nausea/vomiting/gastrointestinal symptoms&#xD;
&#xD;
          -  Have active intracranial bleeding&#xD;
&#xD;
          -  Have active periocular ecchymosis or edema prior to surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thai Do, MD</last_name>
    <phone>248-357-5100</phone>
    <email>tdo@facialworks.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Consultants in Ophthalmic and Facial Plastic Surgery</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48067</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Thai Do, MD</last_name>
      <phone>247-357-5100</phone>
      <email>tdo@facialworks.com</email>
    </contact>
    <investigator>
      <last_name>Dianne Schlachter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan Black, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thai Do, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Kally, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Barmettler, MD</last_name>
      <phone>718-920-5561</phone>
      <email>abarmett@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>70030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amina Malik, MD</last_name>
      <phone>713-441-8843</phone>
      <email>almalik@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas - Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karina Richani, MD</last_name>
      <phone>713-559-5200</phone>
      <email>karina.richanireverol@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Jones, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rohrich RJ, Cho MJ. The Role of Tranexamic Acid in Plastic Surgery: Review and Technical Considerations. Plast Reconstr Surg. 2018 Feb;141(2):507-515. doi: 10.1097/PRS.0000000000003926. Review.</citation>
    <PMID>28938364</PMID>
  </reference>
  <reference>
    <citation>Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, Richter HE, Eder SE, Attia GR, Patrick DL, Rubin A, Shangold GA. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct;116(4):865-875. doi: 10.1097/AOG.0b013e3181f20177.</citation>
    <PMID>20859150</PMID>
  </reference>
  <reference>
    <citation>CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14.</citation>
    <PMID>20554319</PMID>
  </reference>
  <reference>
    <citation>CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2. doi: 10.1016/S0140-6736(11)60278-X.</citation>
    <PMID>21439633</PMID>
  </reference>
  <reference>
    <citation>Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012 Feb;147(2):113-9. doi: 10.1001/archsurg.2011.287. Epub 2011 Oct 17.</citation>
    <PMID>22006852</PMID>
  </reference>
  <reference>
    <citation>Gungorduk K, Yıldırım G, Asıcıoğlu O, Gungorduk OC, Sudolmus S, Ark C. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011 Mar;28(3):233-40. doi: 10.1055/s-0030-1268238. Epub 2010 Oct 26.</citation>
    <PMID>20979013</PMID>
  </reference>
  <reference>
    <citation>Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion. 2008 Mar;48(3):519-25. Epub 2007 Dec 7.</citation>
    <PMID>18067499</PMID>
  </reference>
  <reference>
    <citation>Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG, Pérez-Chrzanowska H, Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014 Dec 3;96(23):1937-44. doi: 10.2106/JBJS.N.00060.</citation>
    <PMID>25471907</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017 Jan 12;376(2):136-148. doi: 10.1056/NEJMoa1606424. Epub 2016 Oct 23. Erratum in: N Engl J Med. 2018 Feb 22;378(8):782.</citation>
    <PMID>27774838</PMID>
  </reference>
  <reference>
    <citation>Choi HY, Hyun SJ, Kim KJ, Jahng TA, Kim HJ. Effectiveness and Safety of Tranexamic Acid in Spinal Deformity Surgery. J Korean Neurosurg Soc. 2017 Jan 1;60(1):75-81. doi: 10.3340/jkns.2016.0505.004. Epub 2016 Dec 29.</citation>
    <PMID>28061495</PMID>
  </reference>
  <reference>
    <citation>Choi WS, Irwin MG, Samman N. The effect of tranexamic acid on blood loss during orthognathic surgery: a randomized controlled trial. J Oral Maxillofac Surg. 2009 Jan;67(1):125-33. doi: 10.1016/j.joms.2008.08.015.</citation>
    <PMID>19070758</PMID>
  </reference>
  <reference>
    <citation>Kumsar S, Dirim A, Toksöz S, Sağlam HS, Adsan O. Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR -P). Cent European J Urol. 2011;64(3):156-8. doi: 10.5173/ceju.2011.03.art13. Epub 2011 Sep 6.</citation>
    <PMID>24578884</PMID>
  </reference>
  <reference>
    <citation>Rannikko A, Pétas A, Taari K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology. 2004 Nov;64(5):955-8.</citation>
    <PMID>15533485</PMID>
  </reference>
  <reference>
    <citation>Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. J Neurosurg. 2002 Oct;97(4):771-8.</citation>
    <PMID>12405362</PMID>
  </reference>
  <reference>
    <citation>Zahed R, Mousavi Jazayeri MH, Naderi A, Naderpour Z, Saeedi M. Topical Tranexamic Acid Compared With Anterior Nasal Packing for Treatment of Epistaxis in Patients Taking Antiplatelet Drugs: Randomized Controlled Trial. Acad Emerg Med. 2018 Mar;25(3):261-266. doi: 10.1111/acem.13345. Epub 2017 Dec 9.</citation>
    <PMID>29125679</PMID>
  </reference>
  <reference>
    <citation>Wand O, Guber E, Guber A, Epstein Shochet G, Israeli-Shani L, Shitrit D. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial. Chest. 2018 Dec;154(6):1379-1384. doi: 10.1016/j.chest.2018.09.026. Epub 2018 Oct 12.</citation>
    <PMID>30321510</PMID>
  </reference>
  <reference>
    <citation>Sagiv O, Rosenfeld E, Kalderon E, Barazani TB, Zloto O, Martinowitz U, Ben Simon GJ, Zilinsky I. Subcutaneous tranexamic acid in upper eyelid blepharoplasty: a prospective randomized pilot study. Can J Ophthalmol. 2018 Dec;53(6):600-604. doi: 10.1016/j.jcjo.2018.01.006. Epub 2018 Mar 27.</citation>
    <PMID>30502984</PMID>
  </reference>
  <reference>
    <citation>Butz DR, Geldner PD. The Use of Tranexamic Acid in Rhytidectomy Patients. Plast Reconstr Surg Glob Open. 2016 May 25;4(5):e716. doi: 10.1097/GOX.0000000000000745. eCollection 2016 May.</citation>
    <PMID>27579240</PMID>
  </reference>
  <reference>
    <citation>Ausen K, Fossmark R, Spigset O, Pleym H. Randomized clinical trial of topical tranexamic acid after reduction mammoplasty. Br J Surg. 2015 Oct;102(11):1348-53. doi: 10.1002/bjs.9878.</citation>
    <PMID>26349843</PMID>
  </reference>
  <reference>
    <citation>Sakallioğlu Ö, Polat C, Soylu E, Düzer S, Orhan İ, Akyiğit A. The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. Ann Plast Surg. 2015 Apr;74(4):392-6. doi: 10.1097/SAP.0b013e3182a1e527.</citation>
    <PMID>24149401</PMID>
  </reference>
  <reference>
    <citation>Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417-33. Review.</citation>
    <PMID>12825966</PMID>
  </reference>
  <reference>
    <citation>Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001 Aug;86(2):714-5.</citation>
    <PMID>11522029</PMID>
  </reference>
  <reference>
    <citation>Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost. 1993 Aug 2;70(2):238-40.</citation>
    <PMID>8236125</PMID>
  </reference>
  <reference>
    <citation>Tavakoli N, Mokhtare M, Agah S, Azizi A, Masoodi M, Amiri H, Sheikhvatan M, Syedsalehi B, Behnam B, Arabahmadi M, Mehrazi M. Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial. United European Gastroenterol J. 2018 Feb;6(1):46-54. doi: 10.1177/2050640617714940. Epub 2017 Jun 20.</citation>
    <PMID>29435313</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>Post-operative ecchymosis</keyword>
  <keyword>Post-operative edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecchymosis</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

